Best Oncology Companies in Washington, United States
The 68 best Oncology companies in Washington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Seattle Genetics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Washington
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Seattle Genetics Developer of antibody-drug conjugates for the treatment of cancer | $1.1B | 69 mo ago | Acquired | 2,404 | 1998 | — | 1,675 patents Antibody‑drug conjugates and engineered linkers for targeted cancer therapeutics. | — |
| 2 | Sana Biotechnology Developer of engineered cell therapies for treating various human diseases | $821M | 72 mo ago | Public | 328 328 → 258 (-21%) | 2018 | Steve Harr Co-Founder & CEO | 361 patents Engineered cell therapies and gene delivery platforms for regenerative and immunomodulatory medicine. | — |
| 3 | Umoja Biopharma Developer of cancer therapeutics | $263M | 17 mo ago | Series C | 168 | 2019 | Michael Jensen Co-Founder | 132 patents Lentiviral vector production and engineered stem‑cell/immune cell therapies for oncology | — |
| 4 | Profound Bio Developer of novel therapies for the treatment of cancer | $250M | 28 mo ago | Acquired | — | 2018 | Baiteng Zhao CEO | — | — |
| 5 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 3 mo ago | Public | 12 12 → 23 (+92%) | 2002 | — | 107 patents CCR5-targeted biologics for HIV, cancer, inflammation, and NAFLD/NASH therapies | 1 partnership |
| 6 | Silverback Therapeutics Stealth mode immuno-oncology biotech startup | $211M | 69 mo ago | Public | 17 | 2016 | Peter Thompson Co-Founder | 143 patents Develops small‑molecule kinase inhibitors and antibody‑drug conjugates for oncology targets. | — |
| 7 | Outpace Bio Developer of T-cell therapies for cancer treatment | $200M | 23 mo ago | Series B | 48 48 → 73 (+52%) | 2020 | Scott Boyken Co-Founder | — | — |
| 8 | Callio Therapeutics Developer of multi-payload antibody-drug conjugates for cancer treatment | $187M | 15 mo ago | Series A | — | 2024 | Jerome Kirkup Co-Founder & Chief Scientific Officer | — | — |
| 9 | Light Sciences Oncology Photosensitive drugs for cancer and other neoplasms | $182M | 89 mo ago | Deadpooled | 17 | 1994 | — | — | — |
| 10 | Chinook Therapeutics Developer of therapeutics for treating kidney diseases | $180M | 70 mo ago | Acquired | 138 | 2000 | Eric Dobmeier CEO & President | — | — |
| 11 | Calypso Medical Technologies Real-time localization technology for Oncology and radiation therapy | $148M | 183 mo ago | Acqui-Hired | 3,361 3,361 → 7,594 (+126%) | 1948 | — | — | — |
| 12 | calypso medical Calypso Medical develops tumor localization systems designed to accurately and objectively track the location… | $148M | 183 mo ago | Acqui-Hired | 175 | 2000 | — | — | — |
| 13 | OncoResponse Developer of immunotherapies for the treatment of cancer 64Funding top 20%Moat top 21%Patents top 24%Innovation top 27% All 8 signals ▾Fundingtop 20% Moattop 21% Patentstop 24% Innovationtop 27% Growthtop 28% Talentbottom 49% Globalbottom 42% Marketbottom 38% Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 14 mo ago | Series D | 33 | 2015 | Clifford Stocks Founder & CEO | 56 patents LILRB2 immune‑checkpoint antibodies for cancer immunotherapy | — |
| 14 | CTI BioPharma Developer of targeted small molecule therapeutics for blood cancer | $132M | 108 mo ago | Acquired | 25 | 1991 | — | 64 patents Novel heterocyclic small‑molecule therapeutics for hematologic cancers, GVHD, and viral infections | — |
| 15 | Blaze Bioscience Biotechnology company improving cancer patient lives through Tumor Paint technology | $124M | 28 mo ago | Series D | 27 | 2010 | — | 157 patents Patents concentrated in chemistry & materials | — |
| 16 | Nohla Therapeutics Provider of stem-cell transplants with umbilical cord blood as an alternative to bone-marrow transplants | $120M | 95 mo ago | Deadpooled | 48 | 2015 | — | — | — |
| 17 | VentiRx Developing small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer | $120M | 140 mo ago | Acquired | 15 | 2006 | — | — | — |
| 18 | Perspective Therapeutics Developer of image guided targeted alpha-particle therapies for cancer treatment | $109M | 27 mo ago | Public | 116 116 → 147 (+27%) | 1998 | Thijs Spoor Chief Executive Officer | — | 4 job openings · 1 launch |
| 19 | Alder Biopharmaceuticals Humanized monoclonal antibody based therapeutics for migraine and inflammatory diseases | $105M | 99 mo ago | Acquired | 202 | 2004 | — | 313 patents Patents concentrated in chemistry & materials | — |
| 20 | immune design Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases. | $101M | 145 mo ago | Acquired | 50 | 2008 | — | 256 patents Engineered lentiviral/retroviral vectors delivering immunostimulatory genes for cancer therapy | — |
| 21 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 2 mo ago | Series B | 54 | 2021 | John Mulligan Founder & CEO | — | — |
| 22 | Viome Life Sciences Provider of tests to prevent, treat, and cure chronic diseases, and cancer | $92M | 22 mo ago | Series C | 136 | 2016 | Momchilo Vuyisich Co-Founder & Chief Science Officer | — | — |
| 23 | Nativis Developer of a therapeutic device for the treatment of cancer | $64M | 91 mo ago | Series B | 13 | 2002 | — | 81 patents Wireless electromagnetic coil systems for targeted cancer therapy, especially glioblastoma treatment. | — |
| 24 | Theraclone Sciences Discovering human monoclonal antibodies for safe and effective therapeutic product development | $61M | 133 mo ago | Series B | 19 | 2004 | Clifford J Stocks CEO | 225 patents Broadly neutralizing HIV‑1 envelope (Env) trimer monoclonal antibody therapeutics | — |
| 25 | Aptevo Therapeutics Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology | $57M | 14 mo ago | Public | 45 45 → 56 (+24%) | 2016 | Marvin White President and CEO | — | — |
| 26 | Good Therapeutics Developer of protein-based drugs for cancer | $37M | 54 mo ago | Acquired | 23 | 2016 | — | — | — |
| 27 | HDT Bio Developer of immunotherapy for the treatment of cancer & infectious diseases | $31M | 13 mo ago | Seed | 32 32 → 54 (+69%) | 2018 | — | — | 1 award |
| 28 | SEngine Precision Medicine Provider of precision medicine platform based on patient-derived organoids | $27M | 39 mo ago | Series A | 26 | 2015 | — | — | — |
| 29 | EMulate Therapeutics Developer of radiofrequency based devices for treatment of cancers | $23M | 81 mo ago | Public | 13 | 2002 | Bennett M. Butters Founder | — | — |
| 30 | OncoGenex Oncogenex develops novel therapeutics targeting mechamisms of treatment resistance in cancer | $22M | 197 mo ago | Acqui-Hired | 12 | 2000 | — | 3 patents Formulation technologies for antisense oligonucleotide therapeutics | — |
| 31 | Aminex Therapeutics Immuno-oncology company developing novel therapies to empower the immune system | $21M | 44 mo ago | Series B | 9 | 2009 | — | — | — |
| 32 | Talus Provider of drug discovery platform for gene regulators | $20M | 14 mo ago | Seed | 15 | 2020 | Alex Federation Co-Founder & CEO | 27 patents Automotive interior storage and organization systems for floor and cargo compartments | — |
| 33 | Link Immunotherapeutics Developer of immunotherapeutics to treat cancer | $14M | 62 mo ago | Deadpooled | 15 | 2019 | — | — | — |
| 34 | Accipiter Biosciences Developer of de novo protein therapies for complex diseases treatment | $13M | 7 mo ago | Seed | — | 2023 | Javier Castellanos Co-Founder & CTO | — | — |
| 35 | Cancer Targeted Technology Developing targeted small molecule drugs for cancer diagnosis and treatment | $10M | 21 mo ago | Funding Raised | 4 | 2006 | — | 90 patents PSMA-targeted small-molecule drug conjugates for cancer imaging and therapy | — |
| 36 | Atossa Therapeutics Developer of drugs for treating breast cancer | $7M | 64 mo ago | Public | 10 | 2009 | — | 166 patents Sustained‑release endocrine modulators and pulmonary drug formulations using heparin/N‑acetylcysteine. | — |
| 37 | LaZure Scientific Low dose alternating current to heat and preferentially destroy tumour cells | $5M | 176 mo ago | Deadpooled | — | 2006 | Chuck Hill CEO | — | — |
| 38 | Neoleukin Therapeutics Manufacturers of therapeutic proteins to treat immunological disorders | $5M | 184 mo ago | Acquired | 7 | 2003 | Jonathan Drachman CEO & President | — | — |
| 39 | PETX Optimizing breast cancer therapy with advanced imaging technology | $5M | 15 mo ago | Funding Raised | 5 | 2012 | Paul E. Kinahan Co-Founder | — | — |
| 40 | Abacus Bioscience Developer of immunotherapeutics for treating cancer and viral diseases | $4M | 40 mo ago | Series A | 7 | 2015 | Edward Clark Founder and Chair | — | — |
| 41 | Modulus Therapeutics Developer of immune cell therapies for the treatment of solid tumors | $4M | 59 mo ago | Seed | 10 | 2020 | Bryce Daines Co-Founder & CTO | — | — |
| 42 | OncoSenX Developer of lipid nanoparticle and plasmid DNA for cancer therapy | $3M | 59 mo ago | Seed | 13 | 2018 | John Lewis Co-Founder | 4 patents In vivo CAR‑T gene therapy delivery for cancer immunotherapy | — |
| 43 | Advanced Imaging Technologies Ultrasound and Holography based Breast imaging systems | $3M | 205 mo ago | Deadpooled | — | 2004 | Michael Hartwig ex-CEO | — | — |
| 44 | ISM Therapeutics US-based biopharma developing therapeutics based on inositol signaling molecules for cystic fibrosis, cancer… | $3M | 233 mo ago | Seed | — | 1998 | Alexis Traynor-Kaplan Founder & CSO | — | — |
| 45 | Onconome Blood test to assess risk of developing colorectal cancer | $2M | 187 mo ago | Deadpooled | — | 2006 | Ray Cairncross CEO | 7 patents Molecular diagnostic assays and biomarkers for colorectal cancer detection and prognosis | — |
| 46 | CisThera Early-stage drug development company developing therapeutics for cancer, autoimmune diseases, chronic kidney… | $2M | 189 mo ago | Funding Raised | — | 2007 | Don Staunton CEO | 12 patents Therapeutic biologics targeting BCL2 apoptosis regulators and PAI‑1 inhibition. | — |
| 47 | Canzxbio Manufacturer of immunotherapy for cancer | $1M | 81 mo ago | Deadpooled | 4 | 2013 | Jennifer Wu Founder & President | — | — |
| 48 | Alpine Immune Sciences Developer of immunotherapies to treat cancer and autoimmune disorders | $1M | 57 mo ago | Acquired | 126 | 2015 | — | 330 patents Engineered ICOS ligand protein therapeutics for immune modulation in cancer treatment | — |
| 49 | RadioGel Developing innovative radionuclide therapy for solid tumors, currently in clinical trials | $725K | 92 mo ago | Series A | 1 | 2006 | Carlton Cadwell Founder | — | — |
| 50 | RJS Biologics Developer of therapeutics for cancer treatment | $225K | 107 mo ago | Funding Raised | 8 | 2009 | Stephen Mccraith Founder | — | — |
Top 12 Oncology companies in Washington
#1
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
#2
Series B · Seattle, Washington · founded 2021 · 54 employees$93Mraised▾
Manufacturer of cytokine based drugs
- Apr 2026Series B$26.9M
- Nov 2022Series A$93M
#3
Series D · Seattle, Washington · founded 2015 · 33 employees$143.6Mraised▾
Developer of immunotherapies for the treatment of cancer. The company uses a proprietary technology platform to discover human antibodies and an immune checkpoint inhibitor (CPI). The company’s lead candidate is OR2805 for the treatment of multiple tumor types.
- Apr 2025Series D$6M
- May 2023Grant (prize money)$13M
- May 2023Series D$14M
- Feb 2022Conventional Debt$50M
#4
Series C · Seattle, Washington · founded 2019 · 168 employees$263Mraised▾
Developer of cancer therapeutics. The company has developed in vivo cellular immunotherapy platform that uses gene therapy to target and attack cancer cells. The company's products include VivoVec that acts through the body’s lymphatic system, to produce cancer-fighting VivoCAR T cells. The company's proprietary RACR/CAR system is used to enhance the activity of VivoCAR T cells. The company's other product includes TumorTag which is used to tag targeted tumor cells/stromal elements.
- Jan 2025Series C$100M
- Jun 2021Series B$210M
- Nov 2020Series A$53M
#5
Series A · Seattle, Washington · founded 2024$187Mraised▾
Developer of multi-payload antibody-drug conjugates for cancer treatment. It develops next-generation antibody-drug conjugates (ADCs) with differentiated payload and linker technologies. This targeted delivery of drug combinations to tumor cells aims to maximize therapeutic benefit for cancer patients. A key focus is on HER2-targeted dual-payload ADCs, and the company is advancing these through clinical proof-of-concept. Research and early development leverage systems biology approaches. Clinical development programs are managed from initial design through to global regulatory approvals. Business development activities include partnerships across multiple therapeutic areas and modalities.
- Mar 2025Series A$187M
#6
Seed · Seattle, Washington · founded 2023$12.7Mraised▾
Developer of de novo protein therapies for complex diseases treatment. These single-agent biologics are custom-engineered to engage multiple pathways. The biologics combine multiple mechanisms in one stable protein molecule. Therapeutic candidates activate more than one cell-surface receptor on the same cell. The platform uses computational methods to create customizable, multifunctional proteins. The company advances a pipeline in autoimmunity and oncology.
- Nov 2025Seed$12.7M
#7
Seed · Seattle, Washington · founded 2018 · 32 employees$30.6Mraised▾
HDT Bio is a developer of immunotherapy for the treatment of cancer & infectious diseases. It enhances the body's immunity power to fight against cancer disease. It increases tumor junctions and improves the disruptive capability. It helps in the tumor penetrance and therefore improves the efficacy, of diverse therapeutics including chemotherapeutics like Paclitaxel, Doxil, Cisplatin, antibodies, oncolytic viruses, and cell therapies. It helps in the treatment of breast cancer, ovarian cancer, and many more. It also provides solutions for pathogen agnostic therapeutics that offer solutions against gram-positive and gram-negative bacteria.
- May 2025Grant (prize money)$2.7M
- May 2025Grant (prize money)$1.6M
- May 2025Grant (prize money)$2.2M
- Apr 2025Grant (prize money)$2M
#8
Public · Seattle, Washington · founded 2016 · 45 employees$57.1Mraised▾
Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology. It is using its proprietary Adaptir platform technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity. It generate immunotherapeutics with mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins. Its pipeline has 4 oncology candidates with the lead Otlertuzumab which induces cell death of primary CLL cells-B-cell tumor lines and also induces NK-cell mediated ADCC and macrophage-mediated phagocytosis for chronic lymphocytic leukemia (CLL).
- Apr 2025Post IPO$2.1M
- Jan 2017Venture Debt$20M
- Aug 2016Conventional Debt$35M
#9
Series B · Seattle, Washington · founded 2020 · 48 employees$200Mraised▾
Developer of T-cell therapies for cancer treatment. The therapies include cell therapy producing controlled Cytokine X, CAR with counter- exhaustion mechanism, cell therapy producing controlled Cytokine Y, and drug-induced gene regulation. These therapies are developed by combining protein design and cell engineering and also with the help of protein design software that custom designs the new biological functions.
- Jul 2024Series B$144M
- Mar 2021Series A$30M
#10
Seed · Seattle, Washington · founded 2020 · 15 employees$19.8Mraised▾
Provider of drug discovery platform for gene regulators. The company provides a functional proteomics platform MARMOT focused on studying full-length GRPs in an unmodified cellular environment. It allows the development of therapeutics against the disease-causing GRPs.
- Apr 2025Grant (prize money)$398.4K
- Feb 2025Grant (prize money)$2M
- Jul 2024Seed$11.2M
- Aug 2023Grant (prize money)$4.3M
#11
Series C · Bothell, Washington · founded 2016 · 136 employees$92.4Mraised▾
Provider of tests to prevent, treat, and cure chronic diseases, and cancer. It uses AI and proprietary mRNA sequencing technology to develop a CancerDetect test for oral & throat cancer. The company platform enables to development of predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases. It has also developed 30 predictive models for Glycemic response, Obesity, Diabetes, Depression, IBS, and Oral Cancer.
- Aug 2024Series C$25.4M
- Oct 2022Series C$67M
#12
Acquired · Woodinville, Washington · founded 2018$250Mraised▾
Developer of novel therapies for the treatment of cancer. The company is involved in the development of CMC for antibody-drug conjugates that kill tumor cells, promote cell rejuvenation, stimulates collagen production and prevents collagen degrading, and more.
- Feb 2024Series B$112M
- Jun 2022Series A$70M
- Jul 2021Series A$55M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology in Washington is moving
A read on the academic research around Oncology in Washington — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 301 papers.
- Washington University in St. Louis145
- University of Washington102
- George Washington University25
- University of Washington Medical Center8
- George Washington University Virginia Campus5
- Tumor microenvironment7→40
- Immunotherapy2→28
- Cancer research6→28
- Immune system7→27
- Cancer1→15
- Tumor microenvironment9→60
- Immune system7→43
- Cancer research8→41
- Immunotherapy8→40
- Cancer4→20
- Tumor microenvironment3→15
- Cancer research1→9
- Cancer3→7
- Pancreatic cancer1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.